드러그인포 약품 상세정보

허가정보

항목

내용

청구코드(KD코드)
비급여점검코드
상한금액

641602240[A04390861] [보험코드에 따른 약품기본정보 직접조회]
\0 원/1개(2006.11.01)(현재약가)
\0 원/1개(2006.02.01)(변경전약가)
[상병코드조회]
[질병코드집 다운로드] [우리집건강주치의 바로가기]

빠른조회


요약정보	[효능] [용법] [금기] [신중투여] [이상반응]

상세정보	[효능] [용법] [경고] [금기] [신중투여] [이상반응] [일반주의] [상호작용] [임산부] [수유부] [소아] [고령자] [신장애환자] [간장애환자] [적용주의] [과량투여] [임상검사치] [보관] [기타]

제품성상

백색-담황백색의 방추형좌제 [제형정보 확인]

포장·유통단위

10개

포장·코드단위

약품규격	단위	대표코드	표준코드	비고
1그램	100 개	8806416022405	8806416022436
1그램	10 개	8806416022405	8806416022429
1그램	1 개	8806416022405	8806416022412

주성분코드

338400CSP [동일한 주성분코드를 가진 오리지날 또는 제네릭 의약품 조회]

대표코드

8806416022405

보관방법

밀폐용기, 실온보관

약리작용

[조회]

효능효과

[적응증 별 검색]

항문열창, 치질의 통증, 가려움, 부종,출혈의 완화

용법용량

* 절대 임의복용하지 마시고 반드시 의사 또는 약사와 상담하시기 바랍니다.

[처방약어]
[주성분코드:338400CSP 에 따른 심사지침열람]

용법용량
성인(15세이상) 1회 1개, 1일1-2회, 항문내에 삽입한다.

[BMI지수 계산] [Body Surface Area 계산] [Cockcroft-Gault GFR 계산] [MDRD GFR 계산]

[피해야 할 음식] [복용을 잊은 경우 대처법]

금기

환부가 화농되어 있는 환자

신중투여

   1) 지금까지 약에 의한 발진, 발적, 가려움 등을 일으킨 일이 있는 사람
   2) 임부 또는 임신하고 있을 가능성이 있는 부인
   3) 의사의 치료를 받고 있는 사람

이상반응

   1) 이 약의 사용에 의하여 발적, 부종, 자극감 또는 화농 등의 증상이 자타날 경우에는 사용을
      중지하고 의사 또는 약사와 상의할 것
   2) 10일정도 사용하여도 증상의 개선이 나타나지 않을 경우에는 사용을 중지하고 의사 또는
      약사와 상의할 것

[주요 이상반응정보]

일반적 주의

   1) 정해진 용법용량을 지킬 것
   2) 이 약이 무르게 된 경우에는 잠시 냉각시킨후에 사용하며 또한 지나치게 경화된 경우에는
      무르게 한후 사용할 것
   3) 이 약은 항문에만 사용하고 내복하지 말 것

보관 및 취급상의 주의

   1) 어린이의 손이 닿지 않는 곳에 보관할 것
   2) 촤제는 체온으로 녹기 쉽도록 제조되어 있기 때문에 직사광선이나 온도가 높은 곳을 피하여
      서늘한 곳에 보관할 것
   3) 오용을 피하고 품질을 보호 유지하기 위해 다른 용기에 넣지 말 것

Related FDA Approved Drug

기준 성분:LIDOCAINE
AKTEN (LIDOCAINE HYDROCHLORIDE)
ALPHACAINE (LIDOCAINE)
ALPHACAINE HYDROCHLORIDE (LIDOCAINE HYDROCHLORIDE)
ALPHACAINE HYDROCHLORIDE W/ EPINEPHRINE (EPINEPHRINE; LIDOCAINE HYDROCHLORIDE)
ANESTACON (LIDOCAINE HYDROCHLORIDE)
DECADRON W/ XYLOCAINE (DEXAMETHASONE SODIUM PHOSPHATE; LIDOCAINE HYDROCHLORIDE)
DENTIPATCH (LIDOCAINE)
DUOCAINE (BUPIVACAINE HYDROCHLORIDE; LIDOCAINE HYDROCHLORIDE)
EMBOLEX (DIHYDROERGOTAMINE MESYLATE; HEPARIN SODIUM; LIDOCAINE HYDROCHLORIDE)
EMLA (LIDOCAINE; PRILOCAINE)
IONTOCAINE (EPINEPHRINE; LIDOCAINE HYDROCHLORIDE)
LANABIOTIC (BACITRACIN ZINC; LIDOCAINE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE)
LARYNG-O-JET KIT (LIDOCAINE HYDROCHLORIDE)
LARYNGOTRACHEAL ANESTHESIA KIT (LIDOCAINE HYDROCHLORIDE)
LIDOCAINE (LIDOCAINE)
LIDOCAINE AND PRILOCAINE (LIDOCAINE; PRILOCAINE)
LIDOCAINE AND TETRACAINE (LIDOCAINE; TETRACAINE)
LIDOCAINE HYDROCHLORIDE (LIDOCAINE HYDROCHLORIDE)
LIDOCAINE HYDROCHLORIDE 0.1% AND DEXTROSE 5% IN PLASTIC CONTAINER (LIDOCAINE HYDROCHLORIDE)
LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER (LIDOCAINE HYDROCHLORIDE)
LIDOCAINE HYDROCHLORIDE 0.2% IN DEXTROSE 5% (LIDOCAINE HYDROCHLORIDE)
LIDOCAINE HYDROCHLORIDE 0.2% IN DEXTROSE 5% IN PLASTIC CONTAINER (LIDOCAINE HYDROCHLORIDE)
LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER (LIDOCAINE HYDROCHLORIDE)
LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5% (LIDOCAINE HYDROCHLORIDE)
LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5% IN PLASTIC CONTAINER (LIDOCAINE HYDROCHLORIDE)
LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER (LIDOCAINE HYDROCHLORIDE)
LIDOCAINE HYDROCHLORIDE 0.8% IN DEXTROSE 5% IN PLASTIC CONTAINER (LIDOCAINE HYDROCHLORIDE)
LIDOCAINE HYDROCHLORIDE 5% AND DEXTROSE 7.5% (LIDOCAINE HYDROCHLORIDE)
LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE (EPINEPHRINE; LIDOCAINE HYDROCHLORIDE)
LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER (LIDOCAINE HYDROCHLORIDE)
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE (LIDOCAINE HYDROCHLORIDE)
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER (LIDOCAINE HYDROCHLORIDE)
LIDOCAINE HYDROCHLORIDE VISCOUS (LIDOCAINE HYDROCHLORIDE)
LIDOCAINE HYDROCHLORIDE W/ EPINEPHRINE (EPINEPHRINE; LIDOCAINE HYDROCHLORIDE)
LIDOCAINE VISCOUS (LIDOCAINE HYDROCHLORIDE)
LIDOCATON (EPINEPHRINE; LIDOCAINE HYDROCHLORIDE)
LIDODERM (LIDOCAINE)
LIDOPEN (LIDOCAINE HYDROCHLORIDE)
LIDOSITE TOPICAL SYSTEM KIT (EPINEPHRINE; LIDOCAINE HYDROCHLORIDE)
LIGNOSPAN FORTE (EPINEPHRINE BITARTRATE; LIDOCAINE HYDROCHLORIDE)
LIGNOSPAN STANDARD (EPINEPHRINE BITARTRATE; LIDOCAINE HYDROCHLORIDE)
LTA II KIT (LIDOCAINE HYDROCHLORIDE)
OCTOCAINE (EPINEPHRINE; LIDOCAINE HYDROCHLORIDE)
ORAQIX (LIDOCAINE; PRILOCAINE)
PEDIATRIC LTA KIT (LIDOCAINE HYDROCHLORIDE)
ROCEPHIN KIT (CEFTRIAXONE SODIUM; LIDOCAINE)
SYNERA (LIDOCAINE; TETRACAINE)
TERRAMYCIN (LIDOCAINE HYDROCHLORIDE; OXYTETRACYCLINE)
XYLOCAINE (LIDOCAINE)
XYLOCAINE 1.5% W/ DEXTROSE 7.5% (LIDOCAINE HYDROCHLORIDE)
XYLOCAINE 4% PRESERVATIVE FREE (LIDOCAINE HYDROCHLORIDE)
XYLOCAINE 5% W/ GLUCOSE 7.5% (LIDOCAINE HYDROCHLORIDE)
XYLOCAINE DENTAL (LIDOCAINE HYDROCHLORIDE)
XYLOCAINE DENTAL WITH EPINEPHRINE (EPINEPHRINE; LIDOCAINE HYDROCHLORIDE)
XYLOCAINE PRESERVATIVE FREE (LIDOCAINE HYDROCHLORIDE)
XYLOCAINE VISCOUS (LIDOCAINE HYDROCHLORIDE)
XYLOCAINE W/ EPINEPHRINE (EPINEPHRINE; LIDOCAINE HYDROCHLORIDE)
ZINGO (LIDOCAINE HYDROCHLORIDE)
기준 성분:ISOPROPYL METHYLPHENOL
기준 성분:ALUMINIUM CHLOROHYDROXY ALLANTOINATE

정보요약

드럭인포 의약품 요약/상세정보

코드 및 분류정보

항목	내용
성분코드	M081425/알란토인클로로히드록시알루미늄 5밀리그램 / M040175/엘멘톨 9밀리그램 / M040131/리도카인 50밀리그램 / M085126/이소프로필메칠페놀 1.6밀리그램 / M040718/초산프레드니솔론 1밀리그램 / M040648/초산토코페롤 20밀리그램 / M051110/염화리소짐 30밀리그램 /
주성분코드	338400CSP [동일한 주성분코드를 가진 오리지날 또는 제네릭 의약품 조회]
대표코드	8806416022405
BIT 약효분류	혈관강화제, 정맥류 치료제, 치질약(Capillary stabilizer, Phlebitis, Varicose veins, Hemorrhoidal)
ATC 코드	AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE / C05A [코드분류상세설명] [ATC코드예측]
복지부분류코드	256 (치질용제 )
주성분코드 분석 및 중복처방 검토	[주성분코드 분석 및 중복처방 검토]
Drugs By Indication	[전체보기]
Drugs By Classification	[전체보기]

제품정보

항목	내용
청구코드(KD코드) 비급여점검코드 상한금액	641602240[A04390861] [보험코드에 따른 약품기본정보 직접조회] \0 원/1개(2006.11.01)(최신약가) \0 원/1개(2006.02.01)(변경전약가) [상병코드조회] [질병코드집 다운로드]
제품성상	백색-담황백색의 방추형좌제 [제형정보 확인]
포장·유통단위	10개
보관방법	밀폐용기, 실온보관
동일주성분코드 검색순위	유료정보입니다.

복약정보

항목

내용

LACTmed 바로가기

[바로가기]

약리작용

유료정보입니다.

축약복약지도

유료정보입니다.

복약지도

유료정보입니다.

임부에대한투여

*	전체임신 기간별로 여러등급이 존재할 수 있으며 가장 위험도가 높은 정보만 보여집니다. 단, 복합제의 경우 모든 복합제성분에 대한 임부투여등급이 표시된것은 절대 아니며 표시된것중에 가장 위험도가 높은 정보만 나타납니다.

FDA : C등급

*	상기 임부투여에 대한 정보는 전산처리 되면서 입력 오류 가능성이 존재합니다. 오류 가능성을 최소화하기 위하여 많은 노력을 기울이고 있으나, 그 정확성에 대하여 확신을 드릴 수 없습니다. 이에 대해 회사는 책임을 지지 않습니다.
*	반드시 공신력 있는 문헌을 다시 한번 참고 하시기 바라며 의사 또는 약사의 판단에 따라 투여여부가 결정되어야 합니다.

신장애, 간장애시
용량조절

유료정보입니다.

병용금기 및 연령대금기 근거조회

[병용금기 및 연령대금기 근거조회]

제형별 복약지도

[좌제]

보관상 주의

조제시 주의

심사정보

항목	내용
DUR 관련 고시	[병용연령금기 의약품 / 임부금기 의약품 / 비용효과적 함량 의약품 / 안전성 관련 급여중지 의약품]

학술정보

항목	내용
DUR (의약품사용평가)	병용금기 : 고시된 병용금기 내용은 없습니다. [상호작용/병용금기검색] 연령대금기 : 고시된 연령금기 내용은 없습니다. [연령대금기상세검색]
독성정보	L-Menthol에 대한 독성정보 : 정보보기 Lidocaine에 대한 독성정보 : 정보보기 Lysozyme에 대한 독성정보 : 정보보기 출처: 국립독성과학원 독성물질정보DB : http://www.nitr.go.kr/nitr/contents/m134200/view.do
Mechanism of Action	Aluminium에 대한 Mechanism_Of_Action 정보 Aluminum Acetate is an astringent. An astrignent is a chemical that tends to shrink or constrict body tissues, usually locally after topical medicinal application. The shrinkage or constriction is through osmotic flow of water (or other fluids) away from the area where the astringent was applied. Astringent medicines cause shrinkage of mucous membranes or exposed tissues and are often used internally to check discharge of blood serum or mucous secretions. This can happen with a sore throat, hemorrhages, diarrhea, or with peptic ulcers. Externally applied astringents, which cause mild coagulation of skin proteins, dry, harden, and protect the skin. Acne sufferers are often advised to use astringents if they have oily skin. Astringents also help heal stretch marks and other scars. Mild astringent solutions are used in the relief of such minor skin irritations as those resulting from superficial cuts, allergies, insect bites, or fungal infections such as athlete's foot. Lidocaine에 대한 Mechanism_Of_Action 정보 Lidocaine stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses thereby effecting local anesthetic action. Prednisolone에 대한 Mechanism_Of_Action 정보 Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.
Pharmacology	Aluminium에 대한 Pharmacology 정보 Not Available Lidocaine에 대한 Pharmacology 정보 Lidocaine is an anesthetic agent indicated for production of local or regional anesthesia and in the treatment of ventricular tachycardia occurring during cardiac manipulation, such as surgery or catheterization, or which may occur during acute myocardial infarction, digitalis toxicity, or other cardiac diseases. The mode of action of the antiarrhythmic effect of Lidocaine appears to be similar to that of procaine, procainamide and quinidine. Ventricular excitability is depressed and the stimulation threshold of the ventricle is increased during diastole. The sinoatrial node is, however, unaffected. In contrast to the latter 3 drugs, Lidocaine in therapeutic doses does not produce a significant decrease in arterial pressure or in cardiac contractile force. In larger doses, lidocaine may produce circulatory depression, but the magnitude of the change is less than that found with comparable doses of procainamide. Prednisolone에 대한 Pharmacology 정보 Prednisolone is a synthetic glucocorticoid used as antiinflammatory or immunosuppressive agent. Prednisolone is indicated in the treatment of various conditions, including congenital adrenal hyperplasia, psoriatic arthritis, systemic lupus erythematosus, bullous dermatitis herpetiformis, seasonal or perennial allergic rhinitis, allergic corneal marginal ulcers, symptomatic sarcoidosis, idiopathic thrombocytopenic purpura in adults, leukemias and lymphomas in adults, and ulcerative colitis. Glucocorticoids are adrenocortical steroids and cause profound and varied metabolic effects. In addition, they modify the body's immune responses to diverse stimuli.
Metabolism	Lidocaine에 대한 Metabolism 정보 # Phase_1_Metabolizing_Enzyme:Cytochrome P450 1A2 (CYP1A2)Cytochrome P450 2D6 (CYP2D6) Prednisolone에 대한 Metabolism 정보 # Phase_1_Metabolizing_Enzyme:Cytochrome P450 3A4 (CYP3A4)
Protein Binding	Aluminium에 대한 단백결합 정보 Not Available Lidocaine에 대한 단백결합 정보 60-80% Prednisolone에 대한 단백결합 정보 Very high (>90%)
Half-life	Aluminium에 대한 반감기 정보 Not Available Lidocaine에 대한 반감기 정보 109 minutes Prednisolone에 대한 반감기 정보 2-3 hours
Absorption	Lidocaine에 대한 Absorption 정보 Information derived from diverse formulations, concentrations and usages reveals that lidocaine is completely absorbed following parenteral administration, its rate of absorption depending, for example, upon various factors such as the site of administration and the presence or absence of a vasoconstrictor agent. Prednisolone에 대한 Absorption 정보 Readily absorbed by gastrointestinal tract, peak plasma concentration is reached 1-2 hours after administration.
Biotransformation	Aluminium에 대한 Biotransformation 정보 Not Available Lidocaine에 대한 Biotransformation 정보 Primarily hepatic. Prednisolone에 대한 Biotransformation 정보 Excreted in the urine as either free or glucoconjugate.
Toxicity	Lidocaine에 대한 Toxicity 정보 The oral LD 50 of lidocaine HCl in non-fasted female rats is 459 (346-773) mg/kg (as the salt) and 214 (159-324) mg/kg (as the salt) in fasted female rats. Symptoms of overdose include convulsions, hypoxia, acidosis, bradycardia, arrhythmias and cardiac arrest. Prednisolone에 대한 Toxicity 정보 LD₅₀=500 mg/kg (oral, rat), short-term side effects include high blood glucose levels and fluid retention. Long term side effects include Cushing's syndrome, weight gain, osteoporosis, glaucoma, type II diabetes and adrenal suppression.
Drug Interactions	Aluminium에 대한 Drug_Interactions 정보 Cyclosporine Synercid increases the effect of cyclosporineAmlodipine This combination presents an increased risk of toxicityArsenic trioxide This combination presents an increased risk of toxicityAstemizole This combination presents an increased risk of toxicityAtorvastatin This combination presents an increased risk of toxicityCarbamazepine This combination presents an increased risk of toxicityCerivastatin This combination presents an increased risk of toxicityCisapride This combination presents an increased risk of toxicityClarithromycin This combination presents an increased risk of toxicityDelavirdine This combination presents an increased risk of toxicityDiazepam This combination presents an increased risk of toxicityDihydroquinidine barbiturate This combination presents an increased risk of toxicityDiltiazem This combination presents an increased risk of toxicityDisopyramide This combination presents an increased risk of toxicityDocetaxel This combination presents an increased risk of toxicityDofetilide This combination presents an increased risk of toxicityDroperidol This combination presents an increased risk of toxicityErythromycin This combination presents an increased risk of toxicityEtoposide This combination presents an increased risk of toxicityFelbamate This combination presents an increased risk of toxicityFelodipine This combination presents an increased risk of toxicityFlecainide This combination presents an increased risk of toxicityFoscarnet This combination presents an increased risk of toxicityFosphenytoin This combination presents an increased risk of toxicityGatifloxacin This combination presents an increased risk of toxicityGrepafloxacin This combination presents an increased risk of toxicityHalofantrine This combination presents an increased risk of toxicityIndinavir This combination presents an increased risk of toxicityIsradipine This combination presents an increased risk of toxicityLercanidipine This combination presents an increased risk of toxicityLevofloxacin This combination presents an increased risk of toxicityLosartan This combination presents an increased risk of toxicityLevomethadyl Acetate This combination presents an increased risk of toxicityLidocaine This combination presents an increased risk of toxicityLovastatin This combination presents an increased risk of toxicityMethylprednisolone This combination presents an increased risk of toxicityMidazolam This combination presents an increased risk of toxicityMoexipril This combination presents an increased risk of toxicityMoxifloxacin This combination presents an increased risk of toxicityNevirapine This combination presents an increased risk of toxicityNicardipine This combination presents an increased risk of toxicityNifedipine Synercid increases the effect of ziprasidoneNimodipine This combination presents an increased risk of toxicityNisoldipine This combination presents an increased risk of toxicityOctreotide This combination presents an increased risk of toxicityPaclitaxel This combination presents an increased risk of toxicityPentamidine This combination presents an increased risk of toxicityQuetiapine This combination presents an increased risk of toxicityQuinidine This combination presents an increased risk of toxicityQuinidine barbiturate This combination presents an increased risk of toxicityRitonavir This combination presents an increased risk of toxicitySalmeterol This combination presents an increased risk of toxicitySimvastatin This combination presents an increased risk of toxicityTacrolimus This combination presents an increased risk of toxicityTamoxifen This combination presents an increased risk of toxicityTeniposide This combination presents an increased risk of toxicityTerfenadine This combination presents an increased risk of toxicityTizanidine This combination presents an increased risk of toxicityVenlafaxine This combination presents an increased risk of toxicityVerapamil This combination presents an increased risk of toxicityVinblastine This combination presents an increased risk of toxicityVincristine This combination presents an increased risk of toxicityVindesine This combination presents an increased risk of toxicityVinorelbine This combination presents an increased risk of toxicity Lidocaine에 대한 Drug_Interactions 정보 Not Available Prednisolone에 대한 Drug_Interactions 정보 Ambenonium The corticosteroid decreases the effect of anticholinesterasesEdrophonium The corticosteroid decreases the effect of anticholinesterasesNeostigmine The corticosteroid decreases the effect of anticholinesterasesPyridostigmine The corticosteroid decreases the effect of anticholinesterasesWarfarin The corticosteroid alters the anticoagulant effectAcenocoumarol The corticosteroid alters the anticoagulant effectDicumarol The corticosteroid alters the anticoagulant effectAnisindione The corticosteroid alters the anticoagulant effectMidodrine Increased arterial pressureAspirin The corticosteroid decreases the effect of salicylatesBismuth Subsalicylate The corticosteroid decreases the effect of salicylatesSalicylate-magnesium The corticosteroid decreases the effect of salicylatesSalicylate-sodium The corticosteroid decreases the effect of salicylatesSalsalate The corticosteroid decreases the effect of salicylatesTrisalicylate-choline The corticosteroid decreases the effect of salicylatesTalbutal The barbiturate decreases the effect of the corticosteroidSecobarbital The barbiturate decreases the effect of the corticosteroidQuinidine barbiturate The barbiturate decreases the effect of the corticosteroidPrimidone The barbiturate decreases the effect of the corticosteroidPhenobarbital The barbiturate decreases the effect of the corticosteroidPentobarbital The barbiturate decreases the effect of the corticosteroidMethylphenobarbital The barbiturate decreases the effect of the corticosteroidMethohexital The barbiturate decreases the effect of the corticosteroidHexobarbital The barbiturate decreases the effect of the corticosteroidHeptabarbital The barbiturate decreases the effect of the corticosteroidDihydroquinidine barbiturate The barbiturate decreases the effect of the corticosteroidButethal The barbiturate decreases the effect of the corticosteroidButalbital The barbiturate decreases the effect of the corticosteroidButabarbital The barbiturate decreases the effect of the corticosteroidAprobarbital The barbiturate decreases the effect of the corticosteroidAmobarbital The barbiturate decreases the effect of the corticosteroidChlorotrianisene The estrogenic agent increases the effect of the corticosteroidClomifene The estrogenic agent increases the effect of the corticosteroidDiethylstilbestrol The estrogenic agent increases the effect of the corticosteroidEstradiol The estrogenic agent increases the effect of the corticosteroidEstriol The estrogenic agent increases the effect of the corticosteroidConjugated Estrogens The estrogenic agent increases the effect of the corticosteroidEstrone The estrogenic agent increases the effect of the corticosteroidEstropipate The estrogenic agent increases the effect of the corticosteroidEthinyl Estradiol The estrogenic agent increases the effect of the corticosteroidMestranol The estrogenic agent increases the effect of the corticosteroidQuinestrol The estrogenic agent increases the effect of the corticosteroidEthotoin The enzyme inducer decreases the effect of the corticosteroidFosphenytoin The enzyme inducer decreases the effect of the corticosteroidMephenytoin The enzyme inducer decreases the effect of the corticosteroidPhenytoin The enzyme inducer decreases the effect of the corticosteroidRifampin The enzyme inducer decreases the effect of the corticosteroidItraconazole The imidazole increases the effect and toxicity of the corticosteroidKetoconazole The imidazole increases the effect and toxicity of the corticosteroid
CYP450 Drug Interaction	[CYP450 Table직접조회]
Food Interaction	Lidocaine에 대한 Food Interaction 정보 Not Available Prednisolone에 대한 Food Interaction 정보 Take with food to reduce gastric irritation.Avoid alcohol. Avoid caffeine.
Drug Target	[Drug Target]
Description	Aluminium에 대한 Description 정보 A metallic element that has the atomic number 13, atomic symbol Al, and atomic weight 26.98. [PubChem] Lidocaine에 대한 Description 정보 A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of procaine but its duration of action is shorter than that of bupivacaine or prilocaine. [PubChem] Prednisolone에 대한 Description 정보 A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]
Dosage Form	Aluminium에 대한 Dosage_Form 정보 Aerosol OralAerosol TopicalCapsule OralCream TopicalEmulsion TopicalGel DentalGel TopicalLiquid DentalLiquid OralLiquid SublingualLiquid TopicalLotion TopicalPaste OralPowder OralPowder TopicalSolution TopicalSolution / drops OralSpray TopicalStick TopicalSuspension OralSuspension TopicalTablet Oral Lidocaine에 대한 Dosage_Form 정보 Aerosol TopicalAerosol, metered TopicalCream TopicalGel TopicalJelly TopicalJelly UrethralLiquid BuccalLiquid DentalLiquid InfiltrationLiquid IntravenousLiquid OralLiquid TopicalLotion TopicalOintment TopicalSolution InfiltrationSolution IntramuscularSolution IntravenousSolution OralSolution TopicalSpray TopicalSwab Topical Prednisolone에 대한 Dosage_Form 정보 Liquid OralSolution OralSolution / drops OphthalmicSuspension OphthalmicTablet Oral
Drug Category	Aluminium에 대한 Drug_Category 정보 Not Available Lidocaine에 대한 Drug_Category 정보 AnestheticsAnesthetics, LocalAnti-Arrhythmia AgentsAntiarrhythmic Agents Prednisolone에 대한 Drug_Category 정보 Adrenergic AgentsAnti-inflammatory AgentsAntineoplastic AgentsAntineoplastic Agents, HormonalGlucocorticoids
Smiles String Canonical	Aluminium에 대한 Smiles_String_canonical 정보 [Al] Lidocaine에 대한 Smiles_String_canonical 정보 CCN(CC)CC(=O)NC1=C(C)C=CC=C1C Prednisolone에 대한 Smiles_String_canonical 정보 CC12CC(O)C3C(CCC4=CC(=O)C=CC34C)C1CCC2(O)C(=O)CO
Smiles String Isomeric	Aluminium에 대한 Smiles_String_isomeric 정보 [Al] Lidocaine에 대한 Smiles_String_isomeric 정보 CCN(CC)CC(=O)NC1=C(C)C=CC=C1C Prednisolone에 대한 Smiles_String_isomeric 정보 C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO
InChI Identifier	Aluminium에 대한 InChI_Identifier 정보 InChI=1/Al Lidocaine에 대한 InChI_Identifier 정보 InChI=1/C14H22N2O/c1-5-16(6-2)10-13(17)15-14-11(3)8-7-9-12(14)4/h7-9H,5-6,10H2,1-4H3,(H,15,17)/f/h15H Prednisolone에 대한 InChI_Identifier 정보 InChI=1/C21H28O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h5,7,9,14-16,18,22,24,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1
Chemical IUPAC Name	Aluminium에 대한 Chemical_IUPAC_Name 정보 aluminum Lidocaine에 대한 Chemical_IUPAC_Name 정보 2-diethylamino-N-(2,6-dimethylphenyl)acetamide Prednisolone에 대한 Chemical_IUPAC_Name 정보 (8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one
Drug-Induced Toxicity Related Proteins	DOCA 의 Drug-Induced Toxicity Related Protein정보 Replated Protein:Aquaporin-2 Drug:DOCA Toxicity:hypertension. [바로가기] LIDOCAINE 의 Drug-Induced Toxicity Related Protein정보 Replated Protein:glucose-regulated protein Drug:lidocaine Toxicity:intestinal disorder. [바로가기] Replated Protein:Alkaline phosphatase Drug:lidocaine Toxicity:lidocaine induced hepatitis. [바로가기] Replated Protein:C-reactive protein Drug:lidocaine Toxicity:fever. [바로가기] Replated Protein:C-reactive protein Drug:lidocaine Toxicity:lidocaine induced hepatitis. [바로가기] Replated Protein:Alpha-1-acid glycoprotein Drug:lidocaine Toxicity:lidocaine tolerance. [바로가기] Replated Protein:Gamma-glutamyltranspeptidase Drug:lidocaine Toxicity:fever. [바로가기] Replated Protein:Alkaline phosphatase Drug:lidocaine Toxicity:fever. [바로가기] Replated Protein:Gamma-glutamyltranspeptidase Drug:lidocaine Toxicity:lidocaine induced hepatitis. [바로가기] PREDNISOLONE 의 Drug-Induced Toxicity Related Protein정보 Replated Protein:DNA topoisomerase 1 Drug:prednisolone Toxicity:appearance of apoptotic cells. [바로가기]

사용자컨텐츠

항목

내용

핵심 요약 정보